We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Reliance Gen. | LSE:GMX | London | Ordinary Share | GB00B1MM9925 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.55 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From May 2019 to May 2024
TIDMGMX
RNS Number : 4616N
Reliance GeneMedix PLC
28 September 2012
FOR IMMEDIATE RELEASE 28 September 2012
Reliance GeneMedix plc
(AIM: GMX)
Result of AGM
The board of Reliance GeneMedix plc ("Reliance GeneMedix" or the "Company") announces that at the Annual General Meeting of the Company's shareholders held today all resolutions were duly passed including those to cancel the admission to trading on AIM of the Ordinary Shares and to re-register the Company as a private limited company. Consequently, it is expected that the last day of dealings in the Ordinary Shares on AIM will be 5 October 2012 and it is expected that the cancellation of admission to trading on AIM of the Ordinary Shares will take effect from 7.00a.m. (British Summer Time) on 8 October 2012. The earliest date that the Company will be re-registered as a private limited company is expected to be 26 October 2012.
If Shareholders wish to buy or sell Ordinary Shares on AIM they must do so prior to the De-Listing becoming effective.
If any of the above dates change, the revised dates will be notified to Shareholders by a further announcement through a Regulatory Information Service. Unless otherwise defined, terms used in this announcement have the meaning given to them in the circular sent to Shareholders on 5 September 2012.
In accordance with AIM Rule 26, a copy of this announcement is available on the Company's website at www.genemedix.com.
ENQUIRIES:
Reliance GeneMedix plc Tel: +353 57 932 3572 Vinay Ranade, Chief Executive Officer Deloitte Corporate Finance Tel: 020 7936 3000 Jonathan Hinton, John Ball Lothbury Financial Services Tel: 020 7868 2567 Michael Padley
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCGMGZLMRNGZZM
1 Year Reliance Genemedix Chart |
1 Month Reliance Genemedix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
